BCL2 and acute myeloid leukemia: BCL2 inhibitor has shown significantly improved clinical outcome in elder AML patients ineligible for standard induction therapy (Pollyea et al, 2018; DiNardo et al, 2019), by altering the mitochondria activity in quiescent leukaemic stem cells, which are generally ROS‐low (Lagadinou et al, 2013).